Serum urate test within six months following allopurinol dispensing
Source: NZ Atlas of Healthcare Variation, Ministry of Health.
Notes: Denominator is people in contact with health services (using Health Tracker). Prevalence may be underestimated by up to 20%. Prevalence rates are not age adjusted.
Around 1,400 Māori aged 20–79 years were estimated to have gout in 2011, giving a crude prevalence of 6%, compared to a crude prevalence of 3% in non-Māori. A third of Māori with gout regularly received allopurinol, a preventive therapy to lower urate levels. Of those who received allopurinol (for gout or other reasons) 41% had a lab test for serum urate levels within the following six months. Forty-seven percent of Māori with gout used non-steroid anti-inflammatory medication.
Table : Hospitalisations for gout, 25 years and over, Auckland DHB, 2011–2013
Note: Ratios in bold show that Māori rates were significantly different from non-Māori rates in the DHB.
There were 33 hospital admissions for gout per year on average among Māori during 2011–2013, much more frequent among males than females. The rate of admission for Māori was 3.7 times that of non-Māori, or 114 more admissions per 100,000.